Hawkey CJ - Search Results

1

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Dallob A, et al. Among authors: hawkey cj. J Clin Pharmacol. 2003 Jun;43(6):573-85. J Clin Pharmacol. 2003. PMID: 12817520 Clinical Trial.

2

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ. Wight NJ, et al. Among authors: hawkey cj. Gastroenterology. 2001 Mar;120(4):867-73. doi: 10.1053/gast.2001.22432. Gastroenterology. 2001. PMID: 11231941 Clinical Trial.

3

Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D. Hawkey CJ, et al. Among authors: hawkey gm. Br J Clin Pharmacol. 2006 Jun;61(6):730-7. doi: 10.1111/j.1365-2125.2006.02644.x. Br J Clin Pharmacol. 2006. PMID: 16722837 Free PMC article.

4

Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.

James MW, Hawkey CJ. James MW, et al. Among authors: hawkey cj. Br J Clin Pharmacol. 2003 Aug;56(2):146-55. doi: 10.1046/j.1365-2125.2003.01934.x. Br J Clin Pharmacol. 2003. PMID: 12895187 Free PMC article. Review.

5

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR. Hawkey CJ, et al. Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. doi: 10.1046/j.1365-2036.2001.00894.x. Aliment Pharmacol Ther. 2001. PMID: 11136272 Review.

6

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.

Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Långström G, Naesdal J, Scheiman JM; NASA1 SPACE1 Study Group. Hawkey C, et al. Am J Gastroenterol. 2005 May;100(5):1028-36. doi: 10.1111/j.1572-0241.2005.41465.x. Am J Gastroenterol. 2005. PMID: 15842575 Clinical Trial.

7

COX-1 and COX-2 inhibitors.

Hawkey CJ. Hawkey CJ. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. Best Pract Res Clin Gastroenterol. 2001. PMID: 11566042 Review.

8

Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.

Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ. Atherton C, et al. Among authors: hawkey cj. Clin Gastroenterol Hepatol. 2004 Feb;2(2):113-20. doi: 10.1016/s1542-3565(03)00318-5. Clin Gastroenterol Hepatol. 2004. PMID: 15017615 Clinical Trial.

9

Gastrointestinal safety of selective COX-2 inhibitors.

Hawkey CJ, Skelly MM. Hawkey CJ, et al. Curr Pharm Des. 2002;8(12):1077-89. doi: 10.2174/1381612023394999. Curr Pharm Des. 2002. PMID: 11945152 Review.

10

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

Donnelly MT, Hawkey CJ. Donnelly MT, et al. Among authors: hawkey cj. Aliment Pharmacol Ther. 1997 Apr;11(2):227-36. doi: 10.1046/j.1365-2036.1997.154330000.x. Aliment Pharmacol Ther. 1997. PMID: 9146759 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

386 results

Search Page

Filters